Skip to main content
M1 Kliniken AG logo

M1 Kliniken AG — Investor Relations & Filings

Ticker · M12 ISIN · DE000A0STSQ8 LEI · 529900W697S31A26WT02 F Human health and social work activities
Open in API
Filings indexed 165 across all filing types
Latest filing 2024-04-26 Transaction in Own Shar…
Country DE Germany
Listing F M12

About M1 Kliniken AG

https://www.m1-kliniken.de/en/index.html

M1 Kliniken AG is a provider of health services in the beauty sector, specializing in aesthetic medicine and plastic surgery. The company operates a chain of specialized medical centers offering a range of treatments, including non-surgical procedures like wrinkle and lip treatments, as well as surgical interventions such as breast corrections. The core of its business model is to provide affordable access to aesthetic treatments while maintaining high quality standards. In addition to its clinical services, the company also offers a portfolio of beauty products.

Recent filings

Filing Released Lang Actions
M1 Kliniken AG decides to start share buyback
Transaction in Own Shares Classification · 100% confidence The document is an 'Ad-hoc' announcement dated April 26, 2024, explicitly stating that 'M1 Kliniken AG decides to start share buyback'. It details the resolution by the Management Board to repurchase up to 1,000,000 shares for a maximum volume of EUR 12,600,000.00. This action directly relates to the company acquiring its own shares. According to the definitions, the category 'Transaction in Own Shares (Code: POS)' covers 'Report of the company buying back or selling its own shares (share repurchase/issuance)'. Although it is an announcement, the core subject matter is the share repurchase itself, making POS the most specific fit over a general RPA or RNS.
2024-04-26 English
M1 Kliniken AG publishes preliminary figures for financial year 2023: M1 continues to grow - sales growth of over 10% to 316,3 million; EBIT increases by 68% to 15.7 million
Earnings Release Classification · 100% confidence The document explicitly states it publishes 'preliminary figures for financial year 2023' and provides key financial metrics like sales growth, EBIT, and equity changes. It uses keywords like 'Preliminary Results/Annual Results' and reports on the full fiscal year (2023). This content structure—announcing preliminary full-year results—is characteristic of an Earnings Release (ER), which typically provides the key highlights before the full Annual Report (10-K) or detailed Management Discussion and Analysis (MDA) is filed. Since it is a preliminary announcement of results, ER is the most appropriate classification over 10-K (which is the final, audited report) or MDA (which is usually a more detailed narrative accompanying the results). The document length (6441 chars) is substantial enough to be more than just a brief announcement, but the focus on 'preliminary figures' points strongly to an ER. FY 2023
2024-04-18 English
Konzernabschluss zum Geschäftsjahr vom 01.01.2022 bis zum 31.12.2022
Annual Report Classification · 100% confidence The document is a comprehensive annual report for M1 Kliniken AG for the fiscal year 2022. It includes the 'Bericht des Aufsichtsrates' (Supervisory Board Report), detailed business segments, organizational structure, and a 'Wirtschaftsbericht' (Management Report/Economic Report). It is clearly a full annual report rather than an announcement or a summary, as it contains detailed financial and operational disclosures. FY 2022
2024-02-20 German
M1 Kliniken AG: Private equity interested in beauty segment, EBITDA of over EUR 27 million expected in 2024
M&A Activity Classification · 99% confidence The document is a short news release dated February 16, 2024, disseminated via EQS-News. It discusses potential interest from private equity in the company's beauty segment and provides an updated EBITDA forecast for 2024. It is not a full financial report (like 10-K or IR), nor is it a transcript (CT) or a formal proxy/dividend notice. It is an announcement regarding strategic corporate activity and financial outlook, which fits best under the general category of a regulatory news service announcement, as it is short and primarily informational/forward-looking, rather than a detailed statutory filing. Given the options, 'Regulatory Filings' (RNS) is the most appropriate fallback for a general corporate news release disseminated via a service like EQS that doesn't fit a more specific category like ER (Earnings Release, which usually contains historical period results) or CAP (Financing Update, which is more specific than general strategic interest). Since it is a news item about potential M&A interest and outlook, RNS serves as the best fit among the provided codes for a general corporate update disseminated through a news wire.
2024-02-16 English
Management Board of M1 Kliniken AG acquires 1.5 million shares in the company and plans an uplisting to the Prime Standard
Director's Dealing Classification · 99% confidence The document is a short news release dated February 5, 2024, announcing that the Management Board members of M1 Kliniken AG acquired 1.5 million shares and are planning an uplisting to the Prime Standard. The key events are insider share purchases (Director's Dealing) and a potential capital structure/listing change. Since the document explicitly details personal share transactions by directors ('Management Board of M1 Kliniken AG... acquired a total of 1.5 million shares'), the most specific category is 'Director's Dealing' (DIRS). While it mentions an uplisting (related to CAP), the primary focus and actionable news item detailed is the insider transaction. It is not a formal regulatory filing like a 10-K or an earnings release, but a specific corporate action announcement.
2024-02-05 English
M1 Kliniken AG: Kilian Brenske, buy
Director's Dealing Classification · 100% confidence The document explicitly states 'Directors’ Dealings' in the title and contains a 'Notification and public disclosure of transactions by persons discharging managerial responsibilities and persons closely associated with them'. It details the name of the director (Kilian Brenske), their position ('Member of the managing body'), and the nature of the transaction ('Acquisition' of shares). This directly matches the definition for Director's Dealing.
2024-02-02 English

Browse filings by year

17 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.